AIMS: To evaluate sodium channel genes as candidates for epilepsy susceptibility and their role in therapeutic efficacy, we screened coding single-nucleotide polymorphism of SCN1A p. Thr 1067 Ala or c.3184 A-->G (rs2298771) and SCN2A p.Arg19Lys or c.56 G-->A (rs17183814) in north Indian epilepsy patients. METHODS: The genotyping was performed in 160 control subjects and 336 patients with epilepsy, of whom 117 were drug resistant and 219 were drug responsive. Therapeutic drug monitoring for phenytoin, carbamazepine, phenobarbital and valproate was also performed in 20% of the patients to confirm compliance. RESULTS: AG genotype of SCN1A 3184 A-->G polymorphism was significantly higher and associated in epilepsy patients [P= 0.005; odds ratio (OR) 1.76, 95% confidence interval (CI) 1.19, 2.61], whereas A variant of SCN2A c.56 G-->A was associated with multiple drug resistance in north Indian patients with epilepsy (P= 0.03; OR 1.62, 95% CI 1.03, 2.56). CONCLUSIONS: Overall, results indicate a differential role of genetic polymorphisms of sodium channels SCN1A and SCN2A in epilepsy susceptibility and drug response.
AIMS: To evaluate sodium channel genes as candidates for epilepsy susceptibility and their role in therapeutic efficacy, we screened coding single-nucleotide polymorphism of SCN1Ap. Thr 1067 Ala or c.3184 A-->G (rs2298771) and SCN2A p.Arg19Lys or c.56 G-->A (rs17183814) in north Indian epilepsypatients. METHODS: The genotyping was performed in 160 control subjects and 336 patients with epilepsy, of whom 117 were drug resistant and 219 were drug responsive. Therapeutic drug monitoring for phenytoin, carbamazepine, phenobarbital and valproate was also performed in 20% of the patients to confirm compliance. RESULTS: AG genotype of SCN1A 3184 A-->G polymorphism was significantly higher and associated in epilepsypatients [P= 0.005; odds ratio (OR) 1.76, 95% confidence interval (CI) 1.19, 2.61], whereas A variant of SCN2A c.56 G-->A was associated with multiple drug resistance in north Indian patients with epilepsy (P= 0.03; OR 1.62, 95% CI 1.03, 2.56). CONCLUSIONS: Overall, results indicate a differential role of genetic polymorphisms of sodium channels SCN1A and SCN2A in epilepsy susceptibility and drug response.
Authors: A Escayg; B T MacDonald; M H Meisler; S Baulac; G Huberfeld; I An-Gourfinkel; A Brice; E LeGuern; B Moulard; D Chaigne; C Buresi; A Malafosse Journal: Nat Genet Date: 2000-04 Impact factor: 38.330
Authors: K Haug; K Hallmann; J Rebstock; J Dullinger; S Muth; F Haverkamp; H Pfeiffer; B Rau; C E Elger; P Propping; A Heils Journal: Epilepsy Res Date: 2001-12 Impact factor: 3.045
Authors: T Sugawara; Y Tsurubuchi; K L Agarwala; M Ito; G Fukuma; E Mazaki-Miyazaki; H Nagafuji; M Noda; K Imoto; K Wada; A Mitsudome; S Kaneko; M Montal; K Nagata; S Hirose; K Yamakawa Journal: Proc Natl Acad Sci U S A Date: 2001-05-22 Impact factor: 11.205
Authors: António F Ambrósio; Patrício Soares-Da-Silva; Caetana M Carvalho; Arsélio P Carvalho Journal: Neurochem Res Date: 2002-02 Impact factor: 3.996
Authors: Yu Jiang; Yujun Han; Slavé Petrovski; Kouros Owzar; David B Goldstein; Andrew S Allen Journal: Am J Hum Genet Date: 2015-07-30 Impact factor: 11.025
Authors: Michael A Gordon; Wu Zhang; Dongyun Yang; Syma Iqbal; Anthony El-Khouiery; Fumio Nagashima; Georg Lurje; Melissa Labonte; Peter Wilson; Andy Sherrod; Robert D Ladner; Heinz-Josef Lenz Journal: Pharmacogenomics Date: 2011-01 Impact factor: 2.533
Authors: Anna C Need; Vandana Shashi; Yuki Hitomi; Kelly Schoch; Kevin V Shianna; Marie T McDonald; Miriam H Meisler; David B Goldstein Journal: J Med Genet Date: 2012-05-11 Impact factor: 6.318